{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:51:16Z","timestamp":1740167476162,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Cleveland Clinic Center for Quantitative Metabolic Research"},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UM1TR004406"],"award-info":[{"award-number":["UM1TR004406"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum Genomics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>We previously identified a genetic subtype (C4) of type 2 diabetes (T2D), benefitting from intensive glycemia treatment in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Here, we characterized the population of patients that met the C4 criteria in the UKBiobank cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Research design and methods<\/jats:title>\n                <jats:p>Using our polygenic score (PS), we identified C4 individuals in the UKBiobank and tested C4 status with risk of developing T2D, cardiovascular disease (CVD) outcomes, and differences in T2D medications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>C4 individuals were less likely to develop T2D, were slightly older at T2D diagnosis, had lower HbA1c values, and were less likely to be prescribed T2D medications (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05). Genetic variants in <jats:italic>MAS1<\/jats:italic> and <jats:italic>IGF2R<\/jats:italic>,  major components of the C4 PS, were associated with fewer overall T2D prescriptions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We have confirmed C4 individuals are a lower risk subpopulation of patients with T2D.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40246-024-00639-z","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T04:01:31Z","timestamp":1719028891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Polygenic subtype identified in ACCORD trial displays a favorable type 2 diabetes phenotype in the UKBiobank population"],"prefix":"10.1186","volume":"18","author":[{"given":"Courtney","family":"Hershberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshiya","family":"Mariam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin M.","family":"Pantalone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B.","family":"Buse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison A.","family":"Motsinger-Reif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Rotroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,22]]},"reference":[{"key":"639_CR1","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes Study Group, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545\u201359.","journal-title":"N Engl J Med"},{"key":"639_CR2","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.2337\/dc20-2700","volume":"44","author":"A Mariam","year":"2021","unstructured":"Mariam A, et al. A type 2 diabetes subtype responsive to ACCORD intensive glycemia treatment. Diabetes Care. 2021;44:1410\u20138.","journal-title":"Diabetes Care"},{"issue":"49","key":"639_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1161\/01.HYP.0000251865.35728.2f","volume":"1979","author":"WO Sampaio","year":"2007","unstructured":"Sampaio WO, et al. Angiotensin-(1\u20137) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertens Dallas Tex. 2007;1979(49):185\u201392.","journal-title":"Hypertens Dallas Tex"},{"key":"639_CR4","doi-asserted-by":"publisher","first-page":"e72266","DOI":"10.7554\/eLife.72266","volume":"11","author":"X Cao","year":"2022","unstructured":"Cao X, et al. ACE2 pathway regulates thermogenesis and energy metabolism. Elife. 2022;11:e72266.","journal-title":"Elife"},{"key":"639_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1530\/EC-16-0098","volume":"6","author":"J Felix Braga","year":"2017","unstructured":"Felix Braga J, RavizzoniDartora D, Alenina N, Bader M, Santos RAS. Glucagon-producing cells are increased in Mas-deficient mice. Endocr Connect. 2017;6:27\u201332.","journal-title":"Endocr Connect"},{"key":"639_CR6","doi-asserted-by":"publisher","first-page":"216383","DOI":"10.1155\/2015\/216383","volume":"2015","author":"S Chanprasertyothin","year":"2015","unstructured":"Chanprasertyothin S, Jongjaroenprasert W, Ongphiphadhanakul B. The association of soluble IGF2R and IGF2R gene polymorphism with type 2 diabetes. J Diabetes Res. 2015;2015:216383.","journal-title":"J Diabetes Res"},{"key":"639_CR7","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779.","journal-title":"PLoS Med"},{"key":"639_CR8","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.biopha.2017.11.020","volume":"97","author":"C-C Feng","year":"2018","unstructured":"Feng C-C, et al. Cardiac apoptosis induced under high glucose condition involves activation of IGF2R signaling in H9c2 cardiomyoblasts and streptozotocin-induced diabetic rat hearts. Biomed Pharmacother. 2018;97:880\u20135.","journal-title":"Biomed Pharmacother"},{"key":"639_CR9","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.ajhg.2019.11.001","volume":"105","author":"F Priv\u00e9","year":"2019","unstructured":"Priv\u00e9 F, Vilhj\u00e1lmsson BJ, Aschard H, Blum MGB. Making the most of clumping and thresholding for polygenic scores. Am J Hum Genet. 2019;105:1213\u201321.","journal-title":"Am J Hum Genet"},{"key":"639_CR10","doi-asserted-by":"publisher","first-page":"e0162388","DOI":"10.1371\/journal.pone.0162388","volume":"11","author":"SV Eastwood","year":"2016","unstructured":"Eastwood SV, et al. Algorithms for the capture and adjudication of prevalent and incident diabetes in UK Biobank. PLoS ONE. 2016;11:e0162388.","journal-title":"PLoS ONE"},{"key":"639_CR11","doi-asserted-by":"publisher","first-page":"e3187","DOI":"10.7717\/peerj.3187","volume":"5","author":"SW Marvel","year":"2017","unstructured":"Marvel SW, et al. Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial. PeerJ. 2017;5:e3187.","journal-title":"PeerJ"},{"key":"639_CR12","unstructured":"R: a language and environment for statistical computing. R Foundation for Statistical Computing; 2017."},{"key":"639_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57:289\u2013300.","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"639_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/EDE.0000000000001316","volume":"32","author":"E Stamatakis","year":"2021","unstructured":"Stamatakis E, et al. Is cohort representativeness pass\u00e9? Poststratified associations of lifestyle risk factors with mortality in the UK Biobank. Epidemiol Camb Mass. 2021;32:179\u201388.","journal-title":"Epidemiol Camb Mass"},{"key":"639_CR15","doi-asserted-by":"publisher","first-page":"H1341","DOI":"10.1152\/ajpheart.00202.2011","volume":"301","author":"G Raffai","year":"2011","unstructured":"Raffai G, Durand MJ, Lombard JH. Acute and chronic angiotensin-(1\u20137) restores vasodilation and reduces oxidative stress in mesenteric arteries of salt-fed rats. Am J Physiol Heart Circ Physiol. 2011;301:H1341-1352.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"639_CR16","doi-asserted-by":"publisher","first-page":"H393","DOI":"10.1152\/ajpheart.00075.2012","volume":"303","author":"PS Guimaraes","year":"2012","unstructured":"Guimaraes PS, et al. Chronic infusion of angiotensin-(1\u20137) into the lateral ventricle of the brain attenuates hypertension in DOCA-salt rats. Am J Physiol Heart Circ Physiol. 2012;303:H393-400.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"639_CR17","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1161\/CIRCHEARTFAILURE.109.905968","volume":"3","author":"Y Wang","year":"2010","unstructured":"Wang Y, et al. Circulating rather than cardiac angiotensin-(1\u20137) stimulates cardioprotection after myocardial infarction. Circ Heart Fail. 2010;3:286\u201393.","journal-title":"Circ Heart Fail"},{"key":"639_CR18","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1161\/01.CIR.0000013847.07035.B9","volume":"105","author":"AE Loot","year":"2002","unstructured":"Loot AE, et al. Angiotensin-(1\u20137) attenuates the development of heart failure after myocardial infarction in rats. Circulation. 2002;105:1548\u201350.","journal-title":"Circulation"},{"key":"639_CR19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2337\/db07-0953","volume":"57","author":"SHS Santos","year":"2008","unstructured":"Santos SHS, et al. Mas deficiency in FVB\/N mice produces marked changes in lipid and glycemic metabolism. Diabetes. 2008;57:340\u20137.","journal-title":"Diabetes"}],"container-title":["Human Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-024-00639-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40246-024-00639-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-024-00639-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T04:04:59Z","timestamp":1719029099000},"score":1,"resource":{"primary":{"URL":"https:\/\/humgenomics.biomedcentral.com\/articles\/10.1186\/s40246-024-00639-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,22]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["639"],"URL":"https:\/\/doi.org\/10.1186\/s40246-024-00639-z","relation":{},"ISSN":["1479-7364"],"issn-type":[{"type":"electronic","value":"1479-7364"}],"subject":[],"published":{"date-parts":[[2024,6,22]]},"assertion":[{"value":"30 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.M.R and K.M.P have received funding from Novo Nordisk and Bayer. K.M.P has also obtained research support from and Merck and Twin Health as well as speaker honoraria from AstraZeneca, Corcept Therapeutics, Merck, and Novo Nordisk, and consulting honoraria from AstraZeneca, Bayer, Corcept Therapeutics, Diasome, Eli Lilly, Merck, Novo Nordisk, and Sanofi. D.M.R has an equity stake in Clarified Precision Medicine and Genovation Health, LLC. JBB\u2019s employer receives contracted consulting fees and travel support for contracted activities by Novo Nordisk; he receives grant support by Bayer, Boehringer-Ingelheim, Carmot, Corcept, Dexcom, Eli Lilly, Insulet, MannKind, Novo Nordisk, and vTv Therapeutics; he is a consultant Alkahest, Altimmune, Anji, Aqua Medical Inc, AstraZeneca, Boehringer-Ingelheim, CeQur, Corcept Therapeutics, Eli Lilly, embecta, GentiBio, Glyscend, Insulet, Mellitus Health, Metsera, Moderna, Pendulum Therapeutics, Praetego, Stability Health, Tandem, Terns Inc, and Vertex; he has provided expert witness testimony for Medtronic MiniMed; he has stock options in Glyscend, Mellitus Health, Pendulum Therapeutics, Praetego, and Stability Health. D.M.R., K.M.P, and A.M have intellectual property related to predicting diabetes subtypes. No other conflicts of interest pertinent to this article were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}